Gaps in Contemporary Echocardiographic Reporting Quality for Mechanisms of Mitral Regurgitation: A Call to Action

Mitral regurgitation (MR) is highly prevalent both in the United States and worldwide and is an important determinant of morbidity and mortality.[1] The mechanisms of MR are divided broadly into primary (affecting valve leaflets) and secondary (affecting nonvalvular structures such as the left ventricle or atrium).2 Mixed MR occurs when primary and secondary mechanisms coexist. In the present study, we refer to “primary degenerative” (e.g., leaflet prolapse and flail) as the type under consideration from a treatment perspective (e.g., rheumatic mitral valve disease is considered relatively less suitable for repair1). Since guideline recommendations for therapeutic options and expected patient outcomes differ by mechanism, proper identification and description of the mechanism of MR are essential to patient care and treatment decisions. [2,3] 

Doppler echocardiography provides the core of the evaluation of valvular regurgitation, and clinician-determined findings are documented in the echocardiographic reports.[2] In addition to the presence and severity of MR, professional multisociety guidelines have defined expectations for echocardiographic reporting, even stating that “one is obligated to describe the mechanism and possible etiologies, particularly in significant regurgitation.”[2] To explore the implementation of these important recommendations in the real-world setting, we developed a natural language processing– (NLP-) based algorithm for identification of relevant descriptors of the mechanism(s) of MR per guidelines by leveraging an extensive database of echocardiographic report data (egnite Database; egnite Inc.).

Federico M. Asch, MD, MedStar Health Research Institute, Washington, DC Georgetown University, Washington, DC 


Rahul P. Sharma, MBBS, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California 


Robert J. Cubeddu, MD, Department of Cardiology, Naples Heart Institute, NCH Healthcare System, Naples, Florida


Philippe Genereux, MD, Department of Cardiovascular Medicine, Morristown Medical Center, Morristown, New Jersey


Michael Dobbles, MS, Kahla Verhoef, BSE, MBA, Michelle Kwon, PhD, egnite Inc., Aliso Viejo, California


Evelio Rodriguez, MD, Ascension Saint Thomas, Nashville, Tennessee


James D. Thomas, MD, Center for Heart Valve Disease, Bluhm Cardiovascular Institute,
Northwestern Medicine, Chicago, Illinois


Linda D. Gillam, MD, MPH, Department of Cardiovascular Medicine, Morristown Medical Center, Morristown, New Jersey

Follow egnite on social:

Related Articles

Press

egnite, Inc. Receives U.S. Patent for NLP-Based Algorithm That Classifies Mitral Regurgitation Mechanism from Echocardiographic Reports

egnite, Inc., a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD to its Medical Advisory Board. Their wealth of expertise in cardiovascular care and dedication to innovation will significantly contribute to egnite’s mission to improve cardiovascular patient care nationwide.

Press

egnite Introduces Customer Access to Its National Cardiovascular Registry and Launches 2026 Call for Science Investigator-Initiated Study Program

egnite, Inc., a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD to its Medical Advisory Board. Their wealth of expertise in cardiovascular care and dedication to innovation will significantly contribute to egnite’s mission to improve cardiovascular patient care nationwide.

egnite Research

Cath Lab Capacity is Up—But Structural Heart Procedures Are Being Outpaced by Other Interventions

Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.